General Characteristics and Mechanism of Action
Integrase inhibitors represent a relatively new yet critical class of antiretroviral drugs. In modern pharmacology, this class is actively studied, and a significant portion of novel molecules with this mechanism of action are still in the stages of development and clinical trials.
The primary goal of these agents is to interrupt the viral life cycle at one of its most critical stages. The mechanism of action involves the prevention of integration. Integration in this context refers to the physical insertion of viral DNA into the host cell's genomic DNA. By blocking this process, the drugs deprive the virus of the ability to use the genetic machinery of the infected cell to produce new viral particles.
Pharmacodynamics and Indications (Raltegravir as a Prototype)
The primary and most extensively studied representative of this group is raltegravir, also known by the trade name Isentress. Pharmacodynamically, its direct target is the integrase enzyme. Raltegravir does not simply bind to the enzyme; it specifically blocks its catalytic center. Deprived of an active catalytic center, the enzyme loses its function, and the viral DNA remains trapped in the cytoplasm, unable to penetrate the genome.
Regarding indications for use, it is essential to recognize that raltegravir is indicated for the treatment of HIV infection in adult patients. Furthermore, it is equally effective against both type 1 (HIV-1) and type 2 (HIV-2) infections. Exam questions often attempt to trick test-takers into choosing only one type or introduce non-existent options (such as a type 3), so remember clearly that the drug works against both major types of human immunodeficiency virus.
Pharmacokinetics and Effect of Food
The pharmacokinetic profile of raltegravir features a distinct characteristic that is clinically vital for patient counseling. The drug is administered exclusively orally. However, its absorption and final blood concentration depend critically on the patient's dietary intake.
A key pharmacokinetic parameter—bioavailability—shows a marked dependence on the presence of dietary fats. If a patient takes the drug with a high-fat meal, the bioavailability of raltegravir increases approximately twofold compared to fasting or a low-fat meal. This twofold increase is a classic example of a food-drug interaction in pharmacology that must be accounted for when prescribing the treatment regimen.
Safety Profile and Tolerability
Despite the seriousness of the disease and the complexity of the mechanism of action, integrase inhibitors in general, and raltegravir in particular, exhibit a very favorable safety profile. Clinical practice demonstrates good tolerability of the drug in the majority of adult patients.
Nevertheless, like any pharmacological agent, raltegravir can cause several adverse effects. The most frequent adverse reactions include:
- Headache;
- Nausea;
- Fatigue.
Knowing these three main adverse effects will help you succeed on pharmacology questions and promptly recognize adverse reactions in clinical practice.